CYP2C9 genotype and association with bone mineral density: A pilot study

Gene

Volumn 526, Issue 2, 2013, Pages 295-298

  Brunner Ziegler, Sophie ^a   Giurgea, Georgiana Aura ^a   Sunder Plassmann, Raute ^a   Hammer, Alexandra ^a   Margeta, Christian ^a   Brunner, Martin ^a   Koppensteiner, Renate ^a   Mannhalter, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CYP2C9 mutation; Glucocorticoid synthesis; Oral anticoagulant treatment; Osteoporosis

Indexed keywords

CYTOCHROME P450 2C9;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PILOT STUDY; PRIORITY JOURNAL;

BMD; BMI; BODY MASS INDEX; BONE MINERAL DENSITY; CYP2C9; CYP2C9 MUTATION; CYTOCHROME P450 2C9; DEXA; DUAL-ENERGY X-RAY ABSORPTIOMETRY; GLUCOCORTICOID SYNTHESIS; ORAL ANTICOAGULANT TREATMENT; OSTEOPOROSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SNP;

ADULT; AGE FACTORS; AGED; ARYL HYDROCARBON HYDROXYLASES; AUSTRALIA; BODY MASS INDEX; BONE DENSITY; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; SEX FACTORS;

EID: 84880750217     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.05.026     Document Type: Article

References (32)

1. "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Academy of Family Physicians) 2005, American Academy of Family Physicians, presented by ABIM Foundation, http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_Amer_Acad_Fam_Phys.pdf, retrieved August 14 2012.
2. Auchus R.J., Miller W.L. Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol. Endocrinol. 1999, 13(7):1169-1182.
3. Bilen O., Teruya J. Complications of anticoagulation. Dis. Mon. 2012, 58(8):440-447.
4. Chen H.Y., Chen W.C., Hsu C.M., Tsai F.J., Tsai C.H. Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 122(1):73-78.
5. Do D.P., et al. Circadian rhythm of cortisol and neighborhood characteristics in a population-based sample: the Multi-Ethnic Study of Atherosclerosis. Health Place 2011, 17(2):625-632.
6. Fareed J., Thethi I., Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu. Rev. Pharmacol. Toxicol. 2012, 52:79-99.
7. Gremmel T., et al. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. Int. J. Cardiol. 2011, (Epub ahead of print).
8. Haiman C.A., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol. Biomark. Prev. 2001, 10(7):743-748.
9. He S.M., Zhou Z.W., Li X.T., Zhou S.F. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr. Med. Chem. 2011, 18(5):667-713.
10. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Rettie AE 2002, 287(13):1690-1698.
11. Holzer G., Grasse A.V., Zehetmayer S., Bencur P., Bieglmayer C., Mannhalter C. Vitamin K epoxide reductase (VKORC1) gene mutations in osteoporosis: a pilot study. Transl. Res. 2010, 156(1):37-44.
12. ICD-10-WHO Version Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 2013, 10. (Revision. Version (2013)).
13. Irusta G., Murphy M.J., Perez W.D., Hennebold J.D. Dynamic expression of epoxyeicosatrienoic acid synthesizing and metabolizing enzymes in the primate corpus luteum. Mol. Hum. Reprod. 2007, 13(8):541-548.
14. Kaur-Knudsen D., Bojesen S.E., Nordestgaard B.G. Cytochrome P450 1B1 and 2C9 genotypes and risk of ischemic vascular disease, cancer, and chronic obstructive pulmonary disease. Curr. Vasc. Pharmacol. 2012, 10(4):512-520.
15. King B.P., Khan T.I., Aithal G.P., Kamali F., Daly A.K. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenet. 2004, 14(12):813-822.
16. Kotzmann H., et al. Effects of 12months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. J. Nephrol. 2004, 17(1):87-94.
17. Krum S.A. Direct transcriptional targets of sex steroid hormones in bone. J. Cell. Biochem. 2011, 112(2):401-408.
18. Liu G., Peacock M., Eilam O., Dorulla G., Braunstein E., Johnston C.C. Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos. Int. 1997, 7(6):564-569.
19. Manolagas S.C., Weinstein R.S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. 1999, 14(7):1061-1106.
20. Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 2010, 123(10):877-884.
21. Morita A., et al. JPOS Study Group. Prediction of bone mineral density from vitamin D receptor polymorphisms is uncertain in representative samples of Japanese Women, The Japanese Population-based Osteoporosis (JPOS) Study. Int. J. Epidemiol. 2004, 33(5):979-988.
22. Nelson H.D., Haney E.M., Dana T., Bougatsos C., Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2010, 153(2):99-111.
23. Niwa T., Yamazaki H. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. Curr. Drug Metab. 2012, 13(8):1145-1159.
24. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004, 29(12):664-673.
25. Ralston S.H. Genetics of osteoporosis. Proc. Nutr. Soc. 2007, 66(2):158-165. (Review).
26. Sakaki T., Kagawa N., Yamamoto K., Inouye K. Metabolism of vitamin D3 by cytochromes P450. Front. Biosci. 2005, 10:119-134.
27. Schlingmann K.P., et al. N. Engl. J. Med. 2011, 365(5):410-421.
28. Somner J., et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 2004, 89(1):344-351.
29. Sono M., Roach M.P., Coulter E.D., Dawson J.H. Heme-containing oxygenases. Chem. Rev. 1996, 7:2841-2888.
30. Thakkinstian A., D'Este C., Attia J. Haplotype analysis of VDR gene polymorphisms: a meta-analysis. Osteoporos. Int. 2004, 15(9):729-734.
31. Williams F., Spector D. Recent advances in the genetics of osteoporosis. J. Musculoskelet. Neuronal. Interact. 2006, 6:27-35.
32. Zajickova K., Zofkova I. Osteoporosis: genetic analysis of multifactorial disease. Endocr. Regul. 2003, 37(1):31-44. (Review).